Compared to Estimates, Cardinal (CAH) Q3 Earnings: A Look at Key Metrics

Core Insights - Cardinal Health reported revenue of $54.91 billion for the quarter ended March 2024, reflecting an 8.8% increase year-over-year, but a -1.63% miss against the Zacks Consensus Estimate of $55.82 billion [1] - The earnings per share (EPS) for the quarter was $2.08, up from $1.74 in the same quarter last year, resulting in a positive surprise of +6.67% compared to the consensus estimate of $1.95 [1] Revenue Breakdown - Pharmaceutical revenue was $50.65 billion, which is an 8.2% increase year-over-year but below the average estimate of $51.89 billion from four analysts [2] - Medical revenue was reported at $3.11 billion, significantly lower than the estimated $3.61 billion, representing a -15.5% change year-over-year [2] - Corporate revenue showed a loss of -$20 million, better than the average estimate of -$2.73 million, with a year-over-year change of +233.3% [2] Segment Profit Analysis - Medical segment profit was $20 million, falling short of the average estimate of $103.19 million from four analysts [2] - Pharmaceutical segment profit was $580 million, also below the estimated $606.65 million from four analysts [2] Stock Performance - Cardinal Health's shares have returned -7.9% over the past month, compared to a -4.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]